Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.
|Original language||English (US)|
|Title of host publication||Kucers the Use of Antibiotics|
|Subtitle of host publication||A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition|
|Number of pages||9|
|State||Published - Jan 1 2017|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)